{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:49:23Z","timestamp":1794473363703,"version":"4.9.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000098","name":"Clinical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00125-025-06461-z","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T02:12:48Z","timestamp":1748484768000},"page":"1889-1898","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prevention of diabetic ketoacidosis in relatives screened for islet autoantibodies and followed up in the TrialNet Pathway to Prevention study at a single institution in Italy"],"prefix":"10.1007","volume":"68","author":[{"given":"Sabina","family":"Martinenghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Merolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Bianconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Senni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Goncharova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Massara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ragogna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bazzigaluppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo R.","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Bonfanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2371-2495","authenticated-orcid":false,"given":"Emanuele","family":"Bosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"issue":"10394","key":"6461_CR1","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1016\/S0140-6736(23)00223-4","volume":"401","author":"T Quattrin","year":"2023","unstructured":"Quattrin T, Mastrandrea LD, Walker LSK (2023) Type 1 diabetes. Lancet 401(10394):2149\u20132162. https:\/\/doi.org\/10.1016\/S0140-6736(23)00223-4","journal-title":"Lancet"},{"issue":"6","key":"6461_CR2","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2337\/dc15-0101","volume":"38","author":"E Bonifacio","year":"2015","unstructured":"Bonifacio E (2015) Predicting type 1 diabetes using biomarkers. Diabetes Care 38(6):989\u201396. https:\/\/doi.org\/10.2337\/dc15-0101","journal-title":"Diabetes Care"},{"issue":"23","key":"6461_CR3","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1001\/jama.2013.6285","volume":"309","author":"AG Ziegler","year":"2013","unstructured":"Ziegler AG, Rewers M, Simell O et al (2013) Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309(23):2473\u20139. https:\/\/doi.org\/10.1001\/jama.2013.6285","journal-title":"JAMA"},{"issue":"10","key":"6461_CR4","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.2337\/dc15-1419","volume":"38","author":"RA Insel","year":"2015","unstructured":"Insel RA, Dunne JL, Atkinson MA et al (2015) Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38(10):1964\u201374. https:\/\/doi.org\/10.2337\/dc15-1419","journal-title":"Diabetes Care"},{"issue":"8","key":"6461_CR5","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2337\/dc16-2228","volume":"40","author":"FK Gorus","year":"2017","unstructured":"Gorus FK, Balti EV, Messaaoui A et al (2017) Belgian Diabetes Registry. Twenty-year progression rate to clinical onset according to autoantibody profile, age, and HLA-DQ genotype in a registry-based group of children and adults with a first-degree relative with type 1 diabetes. Diabetes Care 40(8):1065\u20131072. https:\/\/doi.org\/10.2337\/dc16-2228","journal-title":"Diabetes Care"},{"issue":"8","key":"6461_CR6","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1007\/s00125-020-05152-1","volume":"63","author":"V Cherubini","year":"2020","unstructured":"Cherubini V, Grimsmann JM, \u00c5kesson K et al (2020) Temporal trends in diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes between 2006 and 2016: results from 13 countries in three continents. Diabetologia 63(8):1530\u20131541. https:\/\/doi.org\/10.1007\/s00125-020-05152-1","journal-title":"Diabetologia"},{"issue":"6","key":"6461_CR7","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2337\/diacare.27.6.1399","volume":"27","author":"JM Barker","year":"2004","unstructured":"Barker JM, Goehrig SH, Barriga K et al (2004) DAISY study. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care 27(6):1399\u2013404. https:\/\/doi.org\/10.2337\/diacare.27.6.1399","journal-title":"Diabetes Care"},{"issue":"11","key":"6461_CR8","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.2337\/dc11-1026","volume":"34","author":"H Elding Larsson","year":"2011","unstructured":"Elding Larsson H, Vehik K, Bell R et al (2011) TEDDY Study Group; SEARCH Study Group; Swediabkids Study Group; DPV Study Group; Finnish Diabetes Registry Study Group. Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care 34(11):2347\u201352. https:\/\/doi.org\/10.2337\/dc11-1026","journal-title":"Diabetes Care"},{"issue":"4","key":"6461_CR9","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1399-5448.2011.00829.x","volume":"13","author":"C Winkler","year":"2012","unstructured":"Winkler C, Schober E, Ziegler AG, Holl RW (2012) Markedly reduced rate of diabetic ketoacidosis at onset of type 1 diabetes in relatives screened for islet autoantibodies. Pediatr Diabetes 13(4):308\u201313. https:\/\/doi.org\/10.1111\/j.1399-5448.2011.00829.x","journal-title":"Pediatr Diabetes"},{"issue":"3","key":"6461_CR10","doi-asserted-by":"publisher","first-page":"624","DOI":"10.2337\/dc21-0422.10.2337\/dc21-0422","volume":"45","author":"LM Jacobsen","year":"2022","unstructured":"Jacobsen LM, Vehik K, Veijola R et al (2022) TEDDY Study Group. Heterogeneity of DKA incidence and age-specific clinical characteristics in children diagnosed with type 1 diabetes in the TEDDY study. Diabetes Care 45(3):624\u2013633. https:\/\/doi.org\/10.2337\/dc21-0422.10.2337\/dc21-0422","journal-title":"Diabetes Care"},{"issue":"8","key":"6461_CR11","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1111\/pedi.13422","volume":"23","author":"JM Wentworth","year":"2022","unstructured":"Wentworth JM, Oakey H, Craig ME et al (2022) Decreased occurrence of ketoacidosis and preservation of beta cell function in relatives screened and monitored for type 1 diabetes in Australia and New Zealand. Pediatr Diabetes 23(8):1594\u20131601. https:\/\/doi.org\/10.1111\/pedi.13422","journal-title":"Pediatr Diabetes"},{"issue":"2","key":"6461_CR12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/pedi.12541","volume":"19","author":"AM Hekkala","year":"2018","unstructured":"Hekkala AM, Ilonen J, Toppari J, Knip M, Veijola R (2018) Ketoacidosis at diagnosis of type 1 diabetes: effect of prospective studies with newborn genetic screening and follow up of risk children. Pediatr Diabetes 19(2):314\u2013319. https:\/\/doi.org\/10.1111\/pedi.12541","journal-title":"Pediatr Diabetes"},{"issue":"9","key":"6461_CR13","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s00125-023-05953-0","volume":"66","author":"S Hummel","year":"2023","unstructured":"Hummel S, Carl J, Friedl N et al (2023) Fr1da Study Group. Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation. Diabetologia 66(9):1633\u20131642. https:\/\/doi.org\/10.1007\/s00125-023-05953-0","journal-title":"Diabetologia"},{"issue":"5","key":"6461_CR14","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s00125-013-2850-z","volume":"56","author":"S Fredheim","year":"2013","unstructured":"Fredheim S, Johannesen J, Johansen A et al (2013) Danish Society for Diabetes in Childhood and Adolescence. Diabetic ketoacidosis at the onset of type 1 diabetes is associated with future HbA1c levels. Diabetologia 56(5):995\u20131003. https:\/\/doi.org\/10.1007\/s00125-013-2850-z","journal-title":"Diabetologia"},{"issue":"9","key":"6461_CR15","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2337\/dc17-0558","volume":"40","author":"LM Duca","year":"2017","unstructured":"Duca LM, Wang B, Rewers M, Rewers A (2017) Diabetic ketoacidosis at diagnosis of type 1 diabetes predicts poor long-term glycemic control. Diabetes Care 40(9):1249\u20131255. https:\/\/doi.org\/10.2337\/dc17-0558","journal-title":"Diabetes Care"},{"issue":"2","key":"6461_CR16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/pedi12809","volume":"20","author":"LM Duca","year":"2019","unstructured":"Duca LM, Reboussin BA, Pihoker C et al (2019) Diabetic ketoacidosis at diagnosis of type 1 diabetes and glycemic control over time: the SEARCH for diabetes in youth study. Pediatr Diabetes 20(2):172\u2013179. https:\/\/doi.org\/10.1111\/pedi12809","journal-title":"Pediatr Diabetes"},{"issue":"6","key":"6461_CR17","doi-asserted-by":"publisher","first-page":"e3408","DOI":"10.1002\/dmrr.3408","volume":"37","author":"M Michaelis","year":"2021","unstructured":"Michaelis M, Shochat T, Shimon I, Akirov A (2021) Features and long-term outcomes of patients hospitalized for diabetic ketoacidosis. Diabetes Metab Res Rev 37(6):e3408. https:\/\/doi.org\/10.1002\/dmrr.3408","journal-title":"Diabetes Metab Res Rev"},{"issue":"11","key":"6461_CR18","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.2337\/dc20-0187","volume":"43","author":"S Ghetti","year":"2020","unstructured":"Ghetti S, Kuppermann N, Rewers A et al (2020) Pediatric Emergency Care Applied Research Network (PECARN) DKA FLUID Study Group. Cognitive function following diabetic ketoacidosis in children with new-onset or previously diagnosed type 1 diabetes. Diabetes Care 43(11):2768\u20132775. https:\/\/doi.org\/10.2337\/dc20-0187","journal-title":"Diabetes Care"},{"issue":"6","key":"6461_CR19","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.2337\/dc13-1904","volume":"37","author":"FJ Cameron","year":"2014","unstructured":"Cameron FJ, Scratch SE, Nadebaum C et al (2014) DKA Brain Injury Study Group. Neurological consequences of diabetic ketoacidosis at initial presentation of type 1 diabetes in a prospective cohort study of children. Diabetes Care 37(6):1554\u201362. https:\/\/doi.org\/10.2337\/dc13-1904","journal-title":"Diabetes Care"},{"issue":"2","key":"6461_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j1399-5448.2008.00464.x","volume":"10","author":"JL Mahon","year":"2009","unstructured":"Mahon JL, Sosenko JM, Rafkin-Mervis L et al (2009) TrialNet Natural History Committee; Type 1 Diabetes TrialNet Study Group. The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes 10(2):97\u2013104. https:\/\/doi.org\/10.1111\/j1399-5448.2008.00464.x","journal-title":"Pediatr Diabetes"},{"key":"6461_CR21","doi-asserted-by":"publisher","unstructured":"Sims EK, Geyer S, Johnson SB et al (2020) Type 1 Diabetes TrialNet Study Group. Who is enrolling? The path to monitoring in type 1 diabetes TrialNet's pathway to prevention. Diabetes Care 42(12):2228-2236. https:\/\/doi.org\/10.2337\/dc19-0593. Erratum in: Diabetes Care 2020 Apr;43(4):934. https:\/\/doi.org\/10.2337\/dc20-er04","DOI":"10.2337\/dc19-0593"},{"issue":"Suppl 1","key":"6461_CR22","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.2337\/dc24-S002","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee (2024) Diagnosis and classification of diabetes: standards of care in diabetes-2024. Diabetes Care 47(Suppl 1):S20\u2013S42. https:\/\/doi.org\/10.2337\/dc24-S002","journal-title":"Diabetes Care"},{"issue":"7","key":"6461_CR23","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/pedi13406","volume":"23","author":"N Glaser","year":"2022","unstructured":"Glaser N, Fritsch M, Priyambada L et al (2022) ISPAD clinical practice consensus guidelines 2022: diabetic ketoacidosis and hyperglycemic hyperosmolar state. Pediatr Diabetes 23(7):835\u2013856. https:\/\/doi.org\/10.1111\/pedi13406","journal-title":"Pediatr Diabetes"},{"issue":"10","key":"6461_CR24","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S2213-8587(24)00238-9","volume":"12","author":"REJ Besser","year":"2024","unstructured":"Besser REJ, Griffin KJ (2024) Transitioning to stage 3 type 1 diabetes: when to start insulin. Lancet Diabetes Endocrinol 12(10):692\u2013694. https:\/\/doi.org\/10.1016\/S2213-8587(24)00238-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"6461_CR25","doi-asserted-by":"publisher","first-page":"e3777","DOI":"10.1002\/dmrr.3777","volume":"40","author":"AEJ Hendriks","year":"2024","unstructured":"Hendriks AEJ, Marcovecchio ML, Besser REJ et al (2024) INNODIA consortium, the Fr1da Study Group and the GPPAD Study Group. Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes. Diabetes Metab Res Rev 40(2):e3777. https:\/\/doi.org\/10.1002\/dmrr.3777","journal-title":"Diabetes Metab Res Rev"},{"issue":"8","key":"6461_CR26","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.2337\/dci24-0042","volume":"47","author":"M Phillip","year":"2024","unstructured":"Phillip M, Achenbach P, Addala A, Albanese-O\u2019Neill A et al (2024) Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetes Care 47(8):1276\u20131298. https:\/\/doi.org\/10.2337\/dci24-0042","journal-title":"Diabetes Care"},{"issue":"10","key":"6461_CR27","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.1111\/dom.15779","volume":"26","author":"V Cherubini","year":"2024","unstructured":"Cherubini V, Mozzillo E, Iafusco D et al (2024) Follow-up and monitoring programme in children identified in early-stage type 1 diabetes during screening in the general population of Italy. Diabetes Obes Metab 26(10):4197\u20134202. https:\/\/doi.org\/10.1111\/dom.15779","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"6461_CR28","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1210\/clinem\/dgae292","volume":"109","author":"S Pribitzer","year":"2024","unstructured":"Pribitzer S, O\u2019Rourke C, Ylescupidez A et al (2024) Beyond stages: predicting individual time dependent risk for type 1 diabetes. J Clin Endocrinol Metab 109(12):3211\u20133219. https:\/\/doi.org\/10.1210\/clinem\/dgae292","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"6461_CR29","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S2213-8587(22)00141-3","volume":"10","author":"M Ghalwash","year":"2022","unstructured":"Ghalwash M, Dunne JL, Lundgren M et al (2022) Type 1 Diabetes Intelligence Study Group. Two-age islet- autoantibody screening for childhood type 1 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol 10(8):589\u2013596. https:\/\/doi.org\/10.1016\/S2213-8587(22)00141-3","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"6461_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S2352-4642(22)00350-9","volume":"7","author":"M Ghalwash","year":"2023","unstructured":"Ghalwash M, Anand V, Lou O et al (2023) Type 1 Diabetes Intelligence Study Group. Islet autoantibody screening in at-risk adolescents to predict type 1 diabetes until young adulthood: a prospective cohort study. Lancet Child Adolesc Health 7(4):261\u2013268. https:\/\/doi.org\/10.1016\/S2352-4642(22)00350-9","journal-title":"Lancet Child Adolesc Health"},{"issue":"4","key":"6461_CR31","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1001\/jama.2019.21565","volume":"323","author":"AG Ziegler","year":"2020","unstructured":"Ziegler AG, Kick K, Bonifacio E et al (2020) Fr1da Study Group. Yield of a public health screening of children for islet autoantibodies in Bavaria, Germany. JAMA 323(4):339\u2013351. https:\/\/doi.org\/10.1001\/jama.2019.21565","journal-title":"JAMA"},{"issue":"7","key":"6461_CR32","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2337\/dc19-2003","volume":"43","author":"RB McQueen","year":"2020","unstructured":"McQueen RB, Geno Rasmussen C, Waugh K et al (2020) Cost and cost-effectiveness of large-scale screening for type 1 diabetes in Colorado. Diabetes Care 43(7):1496\u20131503. https:\/\/doi.org\/10.2337\/dc19-2003","journal-title":"Diabetes Care"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06461-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-025-06461-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06461-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T20:03:18Z","timestamp":1755547398000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-025-06461-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6461"],"URL":"https:\/\/doi.org\/10.1007\/s00125-025-06461-z","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The sponsor of the trial was the Type 1 Diabetes TrialNet Study Group. The authors would like to extend their gratitude to the thousands of participants and their families who generously contributed to the study, providing data, samples and information of invaluable importance for the advancement of knowledge about type 1 diabetes.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}},{"value":"The data that support the findings of this study are available from the corresponding author. Restrictions apply to the availability of these data, which were used under license from the TrialNet (USA) for the current study and so are not publicly available. Data are, however, available from the corresponding author upon reasonable request and with permission from the TrialNet Consortium.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"We acknowledge the support of the Type 1 Diabetes TrialNet Study Group\u2019s Pathway to Prevention Study for this TrialNet Ancillary Study. The Type 1 Diabetes TrialNet Study Group is a clinical trials network funded by the National Institutes of Health (NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases and The Eunice Kennedy Shriver National Institute of Child Health and Human Development, through the cooperative agreements U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085465, U01 DK085453, U01 DK085461, U01 DK085466, U01 DK085499, U01 DK085504, U01 DK085509, U01 DK103180,U01 DK103153, U01 DK085476, U01 DK103266, U01 DK103282, U01 DK106984,U01 DK106994, U01 DK107013, U01 DK107014, U01 DK106993 and Breakthrough T1D (formerly JDRF). The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or Breakthrough T1D (formerly JDRF).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"EBo was a member of the TrialNet Study Group and had clinical and scientific responsibility for the conduction of TrialNet studies at the centre. PG was the Trial Coordinator. SM, MRP, RB were the physicians responsible for the contact with participants and families for screening and follow-up. EBi, PG, FR and EBa were responsible for the conduction of screening, follow-up and monitoring procedures, including periodic contact, administration of educational tools, execution of immunological and metabolic tests. ES, AG and FM were responsible for the phone and e-mail contacts during 2023 and 2024 with participants for whom there was no further contact after the first screening and those with no updated information during follow-up. SM, AM, ES and FM designed and conducted the statistical analysis. EBo, SM and AM wrote the manuscript. All authors contributed to discussion and reviewed\/edited the manuscript and gave final approval for the paper to be published. EBo is responsible for the integrity of the work as a whole.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}}]}}